Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 24:14:1391844.
doi: 10.3389/fonc.2024.1391844. eCollection 2024.

A three miRNAs panel in paraffin tissue serves as tool for predicting prognosis of renal cell carcinoma

Wenkang Chen #  1   2 , Wuping Wang #  1   3 , Zhengping Zhao  1 , Zhenyu Wen  1   2 , Yingqi Li  1   3 , Zhenjian Ge  1   2 , Yongqing Lai  1   2 , Liangchao Ni  1   2
Affiliations

A three miRNAs panel in paraffin tissue serves as tool for predicting prognosis of renal cell carcinoma

Wenkang Chen et al. Front Oncol. .

Abstract

Background: Renal cell carcinoma (RCC) stands as the most prevalent form of urogenital cancer. However, there is currently no universally accepted method for predicting the prognosis of RCC. MiRNA holds great potential as a prognostic biomarker for RCC.

Methods: A total of 100 cases with complete paraffin specimens and over 5-year follow-up data meeting the requirements were collected. Utilizing the clinical information and follow-up data of the specimens, an information model was developed. The expression levels of eight microRNAs were identified using RT-qPCR. Finally, determine and analyze the clinical application value of these microRNAs as prognostic markers for RCC.

Results: Significant differences were observed in the expression of two types of miRNAs (miR-378a-5p, miR-23a-5p) in RCC tissue, and three types of miRNAs (miR-378a-5p, miR-642a-5p, miR-23a-5p) were found to be linked to the prognosis of RCC. Establish biomarker combinations of miR-378a-5p, miR-642a-5p, and miR-23a-5p to evaluate RCC prognosis.

Conclusion: The combination of three microRNA groups (miR-378a-5p, miR-642a-5p, and miR-23a-5p) identified in paraffin section specimens of RCC in this study holds significant potential as biomarkers for assessing RCC prognosis.

Keywords: biomarker; cancer diagnosis; kidney cancer; miRNA; paraffin tissue; renal cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Expression between survival group and death group There is a significant elevation in the expression level of (A) miR-378a-5p within the survival group, whereas there is a considerable decrease in the expression level of (F) miR-23a-5p. No statistical significance was detected in (B) miR-185a-5p, (C) miR-642a-5p, (D) miR-592, (E) miR-658, (G) miR-487a-3p and (H) miR-33b-5p. *p < 0.05; ns, Non-significant.
Figure 2
Figure 2
Survival curve Elevated levels of (A) miR-378a-5p and (B) miR-642a-5p, along with reduced levels of (C) miR-23a-5p, serve as prognostic protective factors for RCC.
Figure 3
Figure 3
(A) Normal P-P Plot of Regression Standardized Residual The actual observed curve fits well with the predicted curve of the panel. (B) The receiver operating characteristic (ROC) curve analyses for the three miRNA panel (miR-378a-5p, miR-642a-5p, and miR-23a-5p).The combination of these three miRNAs has moderate predictive accuracy.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2021) 71:209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. (2016) 70:93–105. doi: 10.1016/j.eururo.2016.02.029 - DOI - PubMed
    1. Bahadoram S, Davoodi M, Hassanzadeh S, Bahadoram M, Barahman M, Mafakher L. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol. (2022) 39(3):2022. - PubMed
    1. Petejova N, Martinek A. Renal cell carcinoma: Review of etiology, pathophysiology and risk factors. BioMed Pap Med Fac Univ Palacky Olomouc Czech Repub. (2016) 160:183–94. doi: 10.5507/bp.2015.050 - DOI - PubMed
    1. Khanna A, Crane A, Yerram N, Sun D, Ericson K, Lundy SD, et al. . Contemporary management of advanced renal cell carcinoma. Clin Adv Hematol Oncol. (2018) 16:438–46. - PubMed

LinkOut - more resources